With 56.11 million shares changed hands, the volume of the stock remained lighter than its average volume of 129.38 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $0.4263 whereas the lowest price it dropped to was $0.395. The 52-week range on IXHL shows that it touched its highest point at $3.12 and its lowest point at $0.08 during that stretch. Beta for the stock currently stands at 2.72.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of IXHL was down-trending over the past week, with a drop of -62.00%, but this was up by 93.34% over a month. Three-month performance surged to 210.38% while six-month performance fell -77.90%. The stock lost -80.82% in the past year, while it has lost -78.93% so far this year. A look at the trailing 12-month EPS for IXHL yields -1.25 with Next year EPS estimates of -1.56. For the next quarter, that number is -0.29. This implies an EPS growth rate of 16.52% for this year and -62.50% for next year.
Float and Shares Shorts:
At present, 93.70 million IXHL shares are outstanding with a float of 73.14 million shares on hand for trading. On 2025-07-15, short shares totaled 3.95 million, which was 422.0 higher than short shares on 1749772800. In addition to Mr. Joel Bradley Latham as the firm’s President, CEO & Executive Director, Mr. Joseph Swan serves as its CFO, Treasurer & Secretary.
Institutional Ownership:
Through their ownership of 0.088120006 of IXHL’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, IXHL reported revenue of $0.0 and operating income of -$4582000.0. The EBITDA in the recently reported quarter was -$4707000.0 and diluted EPS was -$0.2.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$2.03458 being high and -$2.03458 being low. For IXHL, this leads to a yearly average estimate of -$2.03458.
